GI Dynamics Announces New Commercial Centres Offering EndoBarrier® Therapy in the European Union
2013 Annual General Meeting
Access for Participants by Webcast and Conference Call
GI Dynamics, Inc. Appoints David Maggs, M.D. as Chief Medical Officer
EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.
EndoBarrier® has received regulatory approval and is commercially available for use in select international markets.
EndoBarrier® is not approved for sale in the United States and is considered investigational.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE